Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lidocaine - Orexa

Next Previous
Drug Profile

Lidocaine - Orexa

Alternative Names: ORE-001

Latest Information Update: 14 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orexa
  • Class Acetanilides; Amines; Class Ib antiarrhythmics; Local anaesthetics; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cell membrane permeability inhibitors; Opioid delta receptor agonists; Opioid receptor agonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Anorexia; Postoperative ileus

Most Recent Events

  • 09 Oct 2025 Interim efficacy and adverse events data from a phase II clinical trial in Postoperative ileus (Prevention) released by Orexa
  • 09 Oct 2025 Orexa plans phase IIb/III trials in Postoperative ileus (Prevention)
  • 07 Sep 2025 Orexa plans to initiate a phase II trial for Anorexia nervosa (PO) (CTIS2023-510499-30-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top